[12/10]
WHO ±Û·Î¹ú COVID-19 ¿ªÇÐ µ¿Çâ
(COVID-19 Global Epidemiological Update )
12¿ù ù ÁÖ µ¿¾È Àü ¼¼°è COVID-19 ¹ß»ý·üÀº 400¸¸°Ç ¹Ì¸¸À¸·Î ½Å±Ô»ç·Ê°¡ º¸°íµÇ¾ú°í, ÀÌ´Â Áö³ ÁÖ¿Í À¯»çÇÑ ¾ç»óÀ» ³ªÅ¸³»¾ú´Ù. COVID-19·Î ÀÎÇÑ ½Å±Ô »ç¸ÁÀÚ´Â Àü ¼¼°èÀûÀ¸·Î 73,000¸í ÀÌ»óÀ¸·Î ¾à°£ Áõ°¡Ãß¼¼¿¡ ÀÖÀ¸¸ç À̴ Ưº°È÷ ¹ÌÁÖÁö¿ª ½Å±ÔȯÀÚ ºñÀ²ÀÌ Àüü ½Å±Ô»ç·ÊÀÇ Àý¹ÝÀ» Â÷ÁöÇÏ°í ÀÖÀ¸¸ç, À̹ø ÁÖ¿¡ »õ·Î ¹ß»ýÇÑ COVID-19·Î ÀÎÇØ »ç¸ÁÇÑ ÃÑ ¼öÀÇ 1/3 ÀÌ»óÀ» Â÷ÁöÇÏ¿´´Ù.
À¯·´Áö¿ª¿¡¼ COVID-19 ½Å±Ô»ç·Ê´Â ¿©ÀüÈ÷ ³ôÀº ¹Ý¸é, »õ·Î¿î »ç¸ÁÀÚ´Â 2ÁÖµ¿¾È ÁÖÃãÇÑ Ãß¼¼¿¡ ÀÖ´Ù. 12¿ù ù ÁÖ µ¿¾È µ¿³²¾Æ½Ã¾Æ¿Í ÁöÁßÇØ µ¿ºÎÁö¿ª¿¡¼ ½Å±Ô»ç·Ê´Â °¨¼ÒÇß´Ù. »ç¸ÁÀÚ´Â ÁöÁßÇØ µ¿ºÎÁö¿ª¿¡¼ °¨¼ÒÇß°í µ¿³²¾Æ½Ã¾Æ Áö¿ª¿¡¼ Áõ°¡Çß´Ù. ¾ÆÇÁ¸®Ä« Áö¿ª¿¡¼´Â ½Å±Ô»ç·Ê¿Í »ç¸ÁÀÚ°¡ ´Ù¸¥ Áö¿ª¿¡ ºñÇØ ³·Áö¸¸ »õ·Î¿î »ç·Ê°¡ 9% Áõ°¡Çß´Ù. ¼ÅÂÆò¾ç Áö¿ª¿¡¼´Â À̹ø ÁÖ¿¡ »õ·Î¿î »ç¸ÁÀÚ°¡ ¾à°£ Áõ°¡ÇßÁö¸¸ ÀüüÀûÀ¸·Î´Â ½Å±Ô ȯÀÚ´Â ´Ù¼Ò °¨¼ÒÃß¼¼¿¡ ÀÖ´Ù.
COVID-19 °¨¿°ÀÌ È®»êµÇ±â ½ÃÀÛÇÑ ÀÌÈÄ ÇöÀç(WHO º¸°í, 12¿ù 7ÀÏ ±âÁØ)±îÁö 6,580¸¸°ÇÀÌ ³Ñ´Â ȯÀÚ¿Í 150¸¸¸í ÀÌ»óÀÇ »ç¸ÁÀÚ°¡ º¸°íµÇ¾ú´Ù.
±×¸² 1. COVID-19 È®ÁøÀÚ ÁÖ°£º¸°í(WHO Áö¿ªº° È®ÁøÀÚ, »ç¸ÁÀÚ, as 6 December, 2020)
±×¸² 2. COVID-19 È®ÁøÀÚ ÁÖ°£º¸°í(WHO ¾Æ¸Þ¸®Ä«Áö¿ª, È®ÁøÀÚ, »ç¸ÁÀÚ, as 6 December, 2020)
±×¸² 3. COVID-19 È®ÁøÀÚ ÁÖ°£º¸°í(WHO ¾ÆÇÁ¸®Ä«Áö¿ª È®ÁøÀÚ, »ç¸ÁÀÚ, as 6 December, 2020)
±×¸² 4. COVID-19 È®ÁøÀÚ ÁÖ°£º¸°í(WHO µ¿ºÎÁöÁßÇØÁö¿ª È®ÁøÀÚ, »ç¸ÁÀÚ, as 6 December, 2020)
±×¸² 5. COVID-19 È®ÁøÀÚ ÁÖ°£º¸°í(WHO À¯·´Áö¿ª È®ÁøÀÚ, »ç¸ÁÀÚ, as 6 December, 2020)
±×¸² 5. COVID-19 È®ÁøÀÚ ÁÖ°£º¸°í(WHO µ¿³²¾Æ½Ã¾ÆÁö¿ª È®ÁøÀÚ, »ç¸ÁÀÚ, as 6 December, 2020)
±×¸² 7.COVID-19 È®ÁøÀÚ ÁÖ°£º¸°í(WHO ¼ÅÂÆò¾çÁö¿ª, È®ÁøÀÚ »ç¸ÁÀÚ, as 6 December, 2020)
ÁÖ¿ä ±¹°¡º° COVID-19 È®ÁøÀÚ, Ä¡¸í·ü ¹× ¿ÏÄ¡À²
COVID-19 ±¹¿Ü¹ß»ýÇöȲÀº Áö¿ªº°·Î ¾Æ½Ã¾ÆÁö¿ª 29°³±¹, Áßµ¿Áö¿ª 18°³±¹, ¾Æ¸Þ¸®Ä«Áö¿ª 35°³±¹, À¯·´Áö¿ª 49°³±¹, ¿À¼¼¾Æ´Ï¾ÆÁö¿ª 4°³±¹, ¾ÆÇÁ¸®Ä«Áö¿ª 49°³±¹, ±×¿Ü ±âŸÁö¿ª Æ÷ÇÔÇÏ¿©, Àü¼¼°èÀûÀ¸·Î COVID-19 È®ÁøÀÚ´Â 65,872,391¸í(½Å±Ô 3,970,427¸í), »ç¸ÁÀÚ 1,523,656¸í(½Å±Ô 73,396¸í)À¸·Î º¸°íµÇ¾ú´Ù(2020³â 12¿ù8ÀÏ ±âÁØ).
Globally ÃÑ È®ÁøÀÚ65,872,391¸í(½Å±Ô3,970,427¸í), »ç¸ÁÀÚ 1,523,656¸í(½Å±Ô73,396¸í)
Ç¥1) ¼¼°èº¸°Ç±â±¸(WHO) Áö¿ªº° COVID-10 È®ÁøÀÚ, Ä¡¸í·ü (WHO Áö¿ªº° 12¿ù 8ÀÏÀÚ)
±¸ºÐ
|
¾ÆÇÁ¸®Ä«
|
¾Æ¸Þ¸®Ä«
|
µ¿ºÎÁöÁßÇØ
|
À¯·´
|
µ¿³²¾Æ½Ã¾Æ
|
¼ÅÂÆò¾ç
|
È®ÁøÀÚ(¸í)
|
1 547 607
|
28 062 331
|
4 288 875
|
19 986 964
|
11 071 129
|
914 744
|
»ç¸ÁÀÚ(¸í)
|
34 486
|
746 852
|
107 258
|
448 867
|
168 458
|
17 722
|
Ä¡¸í·ü(CFR)
|
2.23%
|
2.66%
|
2.50%
|
2.25%
|
1.52%
|
1.94%
|
±×¸² 8) COVID-19 È®Áø ±¹°¡ ¹× Áö¿ªº° È®Áø »ç·Ê(2020³â12¿ù8ÀÏÀÚ WHO º¸°í)
Source: WHO Coronavirus disease 2019 (COVID-19) Global Summary Report (as 6 December)
Ç¥ 2) ±¹°¡ ¹× Áö¿ªº° COVID-19 È®Áø ÇöȲ(2020³â12¿ù 8ÀÏÀÚ WHO º¸°í)
Source: WHO Coronavirus disease 2019 (COVID-19) Global Summary Report (as 6 December)
[ÃֽŠ¿¬±¸µ¿Çâ] Coronavirus 2019 (COVID-19)] Highlights
COVID-19 ȯÀÚÀÇ Ä¡¸íÀ², ÀÓ»óƯ¼º, Åð¿øÀ²
COVID?19 patients' clinical characteristics, discharge rate, and fatality rate of meta?analysis
ÀÌ ¿¬±¸´Â COVID-19 ȯÀÚÀÇ ÀÓ»ó µ¥ÀÌÅ͸¦ ±â¹ÝÀ¸·Î COVID-10ȯÀÚÀÇ Åð¿ø·ü ¹× »ç¸Á·üÀ» ºÐ¼®ÇϱâÀ§ÇØ 2019 ³â 12 ¿ùºÎÅÍ 2020 ³â 2 ¿ù±îÁö COVID-19 ȯÀÚÀÇ ÀÓ»ó µ¥ÀÌÅÍ´Â 4 °³ÀÇ µ¥ÀÌÅͺ£À̽º¿¡¼ °Ë»öÇÏ¿´´Ù. COVID-19 ȯÀÚÀÇ ÀÓ»ó Áõ»ó°ú °Ë»ç½Ç °á°ú¸¦ Åë°èÀûÀ¸·Î ºÐ¼®ÇÏ°í ´ÜÀÏ ±º ¸ÞŸ ºÐ¼®À¸·Î Åð¿øÀ² °ú »ç¸Á·üÀ» ¼³¸íÇß´Ù. 10°³ÀÇ ¹®Çå¿¡¼ 1994 ³â ȯÀÚÀÇ ÀÌ¿ë °¡´ÉÇÑ µ¥ÀÌÅÍ°¡ ¿¬±¸¿¡ Æ÷ÇԵǾú´Ù. [»ó¼¼º¸±â]
Source: Johns Hopkins University CSSE COVID 19 Data-Last Updated 8 December, 21:06 (London time)
[JAMA] COVID-19 °¨¿°µÈ »ê¸ð¿¡¼ ÅÂ¾î³ ½Å»ý¾Æ´Â COVID-19 Ç×üº¸À¯ (Antibodies in Infants Born to Mothers With COVID-19 Pneumonia)
JAMA¿¡ ¹ßÇ¥µÈ À̹ø ¿¬±¸´Â COVID-19°¡ È®Áø µÈ 6 ¸íÀÇ ÀÓ»êºÎ¿Í ½Å»ý¾Æ¿¡°Ô »õ·Î¿î Ç÷ûÇÐÀû ±âÁØÀ¸·Î ½Å»ý¾Æ °¨¿°¿¡ ´ëÇÑ º¸´Ù ÀÚ¼¼ÇÑ Á¶»ç ±âÁØÀ» Àû¿ëÇؼ COVID-19¿¡ °¨¿°µÈ ¸ð¼º¿¡°Ô¼ ÅÂ¾î³ ½Å»ý¾ÆÀÇ COVID-19 Ç×ü º¸À¯¿¡ ´ëÇÑ ¿¬±¸¸¦ ¼öÇàÇÏ¿´´Ù. [»ó¼¼º¸±â]
COVID-19 Vaccines ºñ±³: ÈÀÌÀÚ(Pfizer & BioNTech), ¸ð´õ³ª(Moderna) & ¾Æ½ºÆ®¶óÁ¦³×Ä«(AstraZeneca)
¹Ì±¹ ÈÀÌÀÚ¿Í µ¶ÀÎ ¹ÙÀÌ¿À¿£Å×Å©(Pfizer & BioNTech) °³¹ßÇÑ COVID-19 ¹é½Å°ú ¹Ì±¹ ¸ð´õ³ª(Moderna) Á¦¾àȸ»çÀÇ ¹é½Å °³¹ß ¹ßÇ¥¿¡ À̾î, ¿µ±¹°è ´Ù±¹Àû Á¦¾à»ç ¾Æ½ºÆ®¶óÁ¦³×Ä«(AstraZeneca)´Â 23ÀÏ Èıâ ÀÓ»ó½ÃÇè¿¡¼ 90% È¿°ú°¡ ÀÖ´Â °·ÂÇÑ COVID-19 ¹é½ÅÀÇ ÀÓ»ó½ÃÇè °á°ú¸¦ ÀÕ´Þ¾Æ ¹ßÇ¥Çß´Ù. ÀÌÁ¦ Àü¼¼°è´Â Äڷγª19 °¨¿°À» µåµð¾î ³¡³¾ ¹é½ÅÀÌ °³¹ßµÈ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ´Ù. [»ó¼¼º¸±â]
NIH- Remdesivir (·½µ¥½Ãºñ¸£) COVID-19 Ä¡·áÁ¦·Î ½ÂÀÎ
¹Ì±¹ ±¹¸³º¸°Ç¿¬±¸¿ø(NIH)ÀÌ ¼öÇàÇÑ Ç×¹ÙÀÌ·¯½º ·½µ¥½Ãºñ¾î(remdesivir) ÀÓ»ó½ÃÇ迬±¸ °á°ú°¡ NEJM (New England Journal of Medicine.)À» ÅëÇØ ¹ßÇ¥µÇ¾ú´Ù. (https://www.nejm.org/doi/full/10.1056/NEJMoa2007764?query=featured_home)
ÀÌ °á°ú¸¦ ±Ù°Å·Î 5¿ù 1ÀÏ¿¡ ¹Ì±¹ FDA(½Ä¾àó)´Â ·½µ¥½Ãºñ¾î¸¦ ¡¸ÁßÁõ¡¹È¯ÀÚ(»ê¼ÒÆ÷ȵµ <94%, »ê¼Ò Ä¡·á ÇÊ¿ä)¿¡°Ô ±ä±Þ»ç¿ëÇã°¡¸¦ ½ÂÀÎÇÏ¿´À¸¸ç, ÀÌÁ¦ ·½µ¥½Ãºñ¾î°¡ COVID-19ÀÇ Ç¥ÁØ Ä¡·áÁ¦·Î »ç¿ëÇã°¡µÇ¾ú´Ù. [»ó¼¼º¸±â]
[±¹³»Ç÷ÀåÄ¡·á¼º°ø] COVID-19: ¿ÏÄ¡ÀÚ Ç÷ÀåÄ¡·á(Convalescent Plasma)
±¹³» ¼¼ºê¶õ½ºº´¿ø ¿¬±¸ÆÀÀº ¿ÏÄ¡ÀÚ Ç÷Àå(Convalescent Plasma) Ä¡·á¹æ¹ýÀ¸·Î ÀÓ»ó¿¡¼ Coronavirus disease 2019 (COVID-19)ÀÇ ¿ÏÄ¡ »ç·Ê¸¦ º¸°íÇß´Ù. ÀÌ°ÍÀº Çѱ¹¿¡¼ COVID-19¿¡ ´ëÇÑ ¿ÏÄ¡ÀÚ Ç÷Àå Ä¡·á¿¡ ´ëÇÑ Ã¹ ¹ø° ÀÓ»ó ¿ÏÄ¡»ç·ÊÀÌ´Ù. [»ó¼¼º¸±â]
COVID-19 Ä¡·áÁ¦°³¹ß ±Û·Î¹ú Àӻ󿬱¸ ÇÁ·ÎÁ§Æ®ÇöȲ
½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(Äڷγª19) Ä¡·áÁ¦ °³¹ßÀ» À§ÇØ Àü¼¼°è°¡ ³ë·ÂÇÏ°í ÀÖ´Â °¡¿îµ¥, ÇöÀç Äڷγª 19 Ä¡·áÁ¦ °³¹ß°ú °ü·Ã ±¹Á¦ÀûÀ¸·Î Àӻ󿬱¸°¡ 335,815°ÇÀÌ ÁøÇà Áß¿¡ ÀÖ´Ù(2020³â 4¿ù 13ÀÏÀÚ µî·ÏÇöȲ). ¹Ì±¹ ±¹¸³º¸°Ç¿ø NIH ClinicalTrials.gov¿¡ µî·ÏµÇ¾î ÁøÇàÇÏ°í ÀÖ´Â COVID-19 °ü·Ã Àӻ󿬱¸´Â 300¿©°Ç ÀÌ»óÀÌ ÁøÇà Áß¿¡ ÀÖÀ¸¸ç, ¼¼°èº¸°Ç±â±¸(WHO)±¹Á¦Àӻ󿬱¸µî·Ï Ç÷§Æû(World Health Organization's International Clinical Trials Registry Platform, WHO ICTRP)¿¡¼´Â 590°ÇÀÇ ÇÁ·ÎÁ§Æ®°¡ ÇöÀç Àӻ󿬱¸ Áß¿¡ ÀÖ´Ù. [»ó¼¼º¸±â]
NEJM COVID-19 º¸°í [½ÉÇ÷°üÁúȯ ¾à¹°Ä¡·á, »ç¸Á·ü ¿äÀÎ ¿¬±¸(Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19): Angiotensin-converting–enzyme (ACE) inhibitors & angiotensin-receptor blockers (ARBs)]
º» ¿¬±¸´Â The New England Journal of Medicine 2020³â 5¿ù 1ÀÏÀÚ ¹ßÇ¥µÈ COVID-19 ½ÉÇ÷°üÁúȯÀÇ ¾à¹°Ä¡·á- Angiotensin-converting–enzyme (ACE) inhibitors¿Í Angiotensin-receptor blockers (ARBs) »ç¿ë¿¡ ´ëÇÑ ÀáÀçÀû À§Çؼº Æò°¡¿Í »ç¸Á·ü °ü·Ã¿äÀÎ ¿¬±¸ÀÌ´Ù.
º´¿ø ³» »ç¸ÁÀ² Áõ°¡¿Í °ü·ÃÀÖ´Â µ¶¸³¿äÀεéÀº ¾Æ·¡¿Í °°´Ù.
1. 65¼¼ ÀÌ»ó ¿¬·É( (mortality of 10.0%, vs. 4.9% among those ≤65 years of age; odds ratio, 1.93; 95% confidence interval [CI], 1.60 to 2.41) (65 ¼¼ ¹Ì¸¸ÀÇ »ç¸Á·üÀº 10.0 %, »ç¸Á·üÀº 4.9 %)
2. °ü»óµ¿¸Æ Áúȯ(10.2%, vs. 5.2% among those without disease; OR, 2.70; 95% CI, 2.08 to 3.51)
3. ½ÉºÎÀü(15.3%, vs. 5.6% among those without heart failure; OR 2.48; 95% CI, 1.62 to 3.79)
4. ½ÉÀåºÎÁ¤¸Æ(11.5%, vs. 5.6% among those without arrhythmia; OR, 1.95; 95% CI, 1.33 to 2.86)
5. ¸¸¼ºÆó¼â¼ºÆóÁúȯ(14.2%, vs. 5.6% among those without disease; OR, 2.96; 95% CI, 2.00 to 4.40)
6. ÇöÀç Èí¿¬(9.4%, vs. 5.6% among former smokers or nonsmokers; OR, 1.79; 95% CI, 1.29 to 2.47)
¾à¹°Ä¡·á¿Í »ç¸Á·ü°úÀÇ °ü·ÃÀ» ºÐ¼®ÇÑ °á°ú, ACE inhibitors (2.1% vs. 6.1%; OR, 0.33; 95% CI, 0.20 to 0.54) »ç¿ëÀ̳ª, ARB(6.8% vs. 5.7%; OR, 1.23; 95% CI, 0.87 to 1.74) ¾à¹°Ä¡·á´Â º´¿ø³»¿¡¼ »ç¸ÁÀ§ÇèÀ» Áõ°¡½ÃÅ°´Â °Í°ú °ü·ÃÀÌ ¾ø´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. [¿ø¹®º¸±â]
COVID-19: ÁßÁõ ¼ºÀÎȯÀÚ ICU ÆÐÇ÷Áõ °¡À̵å¶óÀÎ
ÁßÁõ±Þ¼ºÈ£Èí±âÁõÈıºÀ» ¾ß±âÇÏ´Â SARS-CoV-2´Â Àü¼¼°èÀûÀ¸·Î ±Þ¼ÓÇÏ°Ô È®»êµÇ°í ÀÖÀ¸¸ç ¼ö¸¹Àº »ç¶÷µéÀÇ »ý¸íÀ» À§ÇùÇÏ°í ÀÖ´Ù. À̵éÀ» µ¹º¸´Â º¸°ÇÀÇ·áÀεé°ú ÀÓ»óÀǻ縦 À§ÇÑ ±ä±ÞÇÑ °¡À̵å¶óÀÎ °³¹ßÀÌ ÇÊ¿äÇÏ´Ù. COVID-19·Î ÀÎÇÑ ÆÐÇ÷Áõ °ü¸® ÁöħÀ» À§ÇØ ±¸¼ºµÈ ÆгÎÀº 54°³ÀÇ Áø¼ú¹®À» ¸¸µé¾ú°í ÀÌÁß¿¡¼ 4°¡Áö º£½ºÆ® ½Ç¹«°¡À̵å¶óÀΰú 9°¡Áö °·ÂÇÑ ±Ç°í»çÇ×°ú, 35°¡Áö Áõ°Å°¡ ºÎÁ·ÇÑ Á¦¾ÈµéÀº ¹ßÇ¥Çß´Ù. [´õº¸±â]
Ç¥ 5) Coronavirus disease (COVID-19) ±¹³» ¹× ±¹¿Ü COVID -19 ÃֽŠÁ¤º¸ ¹Ù·Î°¡±â
Ç¥ 6) Coronavirus disease (COVID-19) ÃֽŠÇмúÁ¤º¸ »çÀÌÆ® ¹Ù·Î°¡±â
ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ Á¦°ø
References
Çѱ¹ : Á߾ӹ濪´ëÃ¥º»ºÎ Á¤·Êºê¸®ÇÎ º¸µµÀÚ·á
WHO, Coronavirus (COVID-19) Situation reports
Áß±¹ : ±¹°¡À§»ý°Ç°À§¿øȸ ȨÆäÀÌÁö
ÀÌÅ»¸®¾Æ : º¸°ÇºÎ ȨÆäÀÌÁö
ÀϺ» : ÈÄ»ý³ëµ¿¼º º¸µµÀÚ·á
¿µ±¹ : Á¤ºÎ»çÀÌÆ®
À̶õ · ¹Ì±¹ : Coronavirus COVID-19 Global Cases by Johns Hopkins CSSE